BR0206434A - Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente - Google Patents

Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente

Info

Publication number
BR0206434A
BR0206434A BR0206434-0A BR0206434A BR0206434A BR 0206434 A BR0206434 A BR 0206434A BR 0206434 A BR0206434 A BR 0206434A BR 0206434 A BR0206434 A BR 0206434A
Authority
BR
Brazil
Prior art keywords
disorder
depression
patient
composition
methods
Prior art date
Application number
BR0206434-0A
Other languages
English (en)
Inventor
Arnold Stan Lippa
Joseph William Epstein
Original Assignee
Dov Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dov Pharmaceutical Inc filed Critical Dov Pharmaceutical Inc
Publication of BR0206434A publication Critical patent/BR0206434A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, COMPOSIçãO, E, MéTODOS DE TRATAMENTO OU DE PREVENçãO DA RECIDIVA DE DEPRESSãO, DE UM DISTúRBIO DE ANSIEDADE, DE UM DISTúRBIO DA ALIMENTAçãO E DE UM DISTúRBIO DE INCONTINêNCIA URINáRIA EM UM PACIENTE". A presente invenção refere-se a (+)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0]hexano e seus sais farmaceuticamente aceitáveis composições compreendendo (+)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0] hexano ou um seu sal farmaceuticamente aceitável, e métodos para o tratamento ou a prevenção de recidiva da depressão, distúrbios de ansiedade, distúrbios da alimentação, ou incontinência urinária em um paciente, compreendendo administrar (+)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0] hexano ou um seu sal farmaceuticamente aceitável. O (+)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0] hexano ou seu sal farmaceuticamente aceitável é substancialmente isento de seu enanciómero (-) correspondente.
BR0206434-0A 2001-01-11 2002-01-11 Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente BR0206434A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/758,883 US6372919B1 (en) 2001-01-11 2001-01-11 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
PCT/US2002/000845 WO2002066427A2 (en) 2001-01-11 2002-01-11 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR0206434A true BR0206434A (pt) 2003-12-30

Family

ID=25053471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206434-0A BR0206434A (pt) 2001-01-11 2002-01-11 Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente

Country Status (19)

Country Link
US (2) US6372919B1 (pt)
EP (1) EP1349835B1 (pt)
JP (4) JP2005500983A (pt)
KR (1) KR20030081384A (pt)
CN (2) CN1496349A (pt)
AU (1) AU2002251758B2 (pt)
BR (1) BR0206434A (pt)
CA (1) CA2434616C (pt)
CZ (1) CZ306143B6 (pt)
HU (1) HUP0302613A3 (pt)
IL (2) IL156889A0 (pt)
MX (1) MXPA03006210A (pt)
NO (1) NO325709B1 (pt)
NZ (1) NZ527101A (pt)
PL (1) PL364837A1 (pt)
RU (1) RU2294926C2 (pt)
SK (1) SK10122003A3 (pt)
WO (1) WO2002066427A2 (pt)
ZA (1) ZA200305440B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20070225351A1 (en) * 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
RU2361862C2 (ru) * 2003-12-29 2009-07-20 Сепракор Инк. Пиррольные и пиразольные ингибиторы daao
EP1773321A2 (en) * 2004-07-22 2007-04-18 Wyeth Method for treating nervous system disorders and conditions
CN101014337A (zh) * 2004-07-22 2007-08-08 惠氏公司 治疗神经系统障碍和病症的方法
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
AU2012203400B2 (en) * 2004-08-18 2015-01-15 Euthymics Bioscience, Inc. Novel polymorphs of azabicyclohexane
KR20130004370A (ko) * 2004-08-18 2013-01-09 도브 파마슈티칼 인코포레이티드 아자비사이클로헥산의 신규한 다형체
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
CA2614282A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
RU2008107336A (ru) * 2005-07-27 2009-09-10 Дов Фармасьютикал, Инк. (Us) Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
US8053603B2 (en) * 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
CA2662538A1 (en) * 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080234354A1 (en) * 2006-11-21 2008-09-25 Lippa Arnold S Methods And Compositions For Controlling Body Weight And Appetite
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
RU2470011C2 (ru) 2007-05-31 2012-12-20 Сепракор Инк. Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
ES2553612T3 (es) 2009-02-09 2015-12-10 Sunovion Pharmaceuticals Inc. Inhibidores de la recaptación triple de pirrolidina
RU2012102094A (ru) 2009-06-26 2013-08-10 Панацеа Биотек Лтд. Новые азабициклогексаны
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2012042539A2 (en) 2010-09-28 2012-04-05 Panacea Biotec Ltd Novel bicyclic compounds
CN102417475A (zh) * 2010-09-28 2012-04-18 江苏恒瑞医药股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的应用
CA2834713A1 (en) * 2010-12-03 2012-06-07 Anthony Alexander Mckinney Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
EP2994129A4 (en) * 2013-05-07 2017-01-25 Euthymic Bioscience, Inc. Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US20230085440A1 (en) 2021-08-31 2023-03-16 Ethismos Research, Inc. Methods of preventing and treating pain and associated symptoms

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892772A (en) 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
JPS535994B2 (pt) 1974-09-26 1978-03-03
US4231935A (en) 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4131611A (en) 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4088652A (en) 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4196120A (en) 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
GR72713B (pt) 1976-09-15 1983-12-01 American Cyanamid Co
US4118393A (en) 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
US4118417A (en) 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
IL65843A (en) 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
CH644580A5 (de) * 1980-01-29 1984-08-15 Hoffmann La Roche Cyclohexen-derivate.
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3324263A1 (de) * 1983-07-06 1985-01-17 Hoechst Ag, 6230 Frankfurt Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung
FI910897A (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
US5130430A (en) 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US20030013740A1 (en) * 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
JP4194715B2 (ja) * 1998-08-31 2008-12-10 大正製薬株式会社 6−フルオロビシクロ[3.1.0]ヘキサン誘導体
JP2000159761A (ja) * 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド
JP4290265B2 (ja) * 1999-03-02 2009-07-01 第一ファインケミカル株式会社 新規な不斉配位子
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent

Also Published As

Publication number Publication date
CA2434616A1 (en) 2002-08-29
JP2014028847A (ja) 2014-02-13
WO2002066427A2 (en) 2002-08-29
HUP0302613A3 (en) 2007-09-28
US20040132797A1 (en) 2004-07-08
CN101461804A (zh) 2009-06-24
NO325709B1 (no) 2008-07-07
CZ20032153A3 (cs) 2003-12-17
RU2294926C2 (ru) 2007-03-10
WO2002066427A3 (en) 2003-03-13
CZ306143B6 (cs) 2016-08-24
JP2005500983A (ja) 2005-01-13
RU2003124649A (ru) 2005-02-27
CA2434616C (en) 2011-03-29
NO20033165L (no) 2003-09-04
PL364837A1 (en) 2004-12-27
CN1496349A (zh) 2004-05-12
US6372919B1 (en) 2002-04-16
MXPA03006210A (es) 2004-10-15
AU2002251758B2 (en) 2008-01-03
US7098229B2 (en) 2006-08-29
EP1349835A2 (en) 2003-10-08
SK10122003A3 (sk) 2003-12-02
NO20033165D0 (no) 2003-07-10
CN101461804B (zh) 2011-04-13
ZA200305440B (en) 2004-07-15
IL156889A (en) 2010-12-30
JP2009280605A (ja) 2009-12-03
HUP0302613A2 (hu) 2003-11-28
IL156889A0 (en) 2004-02-08
EP1349835B1 (en) 2016-03-30
NZ527101A (en) 2005-08-26
JP2015227360A (ja) 2015-12-17
KR20030081384A (ko) 2003-10-17

Similar Documents

Publication Publication Date Title
BR0206434A (pt) Composto, composição, e, métodos de tratamento ou de prevenção da recidiva de depressão, de um distúrbio de ansiedade, de um distúrbio da alimentação e de um distúrbio de incontinência urinária em um paciente
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
MX2007005570A (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0015624A (pt) Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001001973A8 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
GR3022459T3 (en) Quinuclidine derivative as substance p antagonist.
HK1047244A1 (en) Synergistic combination of roflumilast and salmeterol
GB9510037D0 (en) Improvements in or relating to organic compounds
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
BR0010802A (pt) Antagonistas de receptor il-8
MA27539A1 (fr) Nouvelle combinaison synergique contenant du roflumilast et du formoterol
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
NZ293691A (en) Use of a medicament containing an anilide compound for treatment of type i allergic diseases
NO971899D0 (no) Anvendelse av £R-(Z)|-<alfa>-(metoksyimino)-<alfa>-(1 azabicyklo £2.2.2| okt-3-yl) acetonitril til å redusere amyloid <beta>-A4-dannelse hos Alzheimer's sykdom
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/40, A61K 31/403, A61K 31/407, A61K 45/00, A61K 45/06, A61P 1/14, A61P 13/10, A61P 25/00, A61P 25/18, A61P 25/22, A61P 25/24, A61P 25/30, A61P 25/32, A61P 3/04, A61P 7/12, C07D 209/52, C07D 471/08

Ipc: C07D 209/00 (2011.01)

B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. C07D 209/00, A61P 1/14, A61P 13/10, A61P 25/00

Ipc: C07D 209/00 (2006.01), A61P 1/14 (2006.01), A61P 1

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: EUTHYMICS BIOSCIENCE, INC. (US)